Home > Journals > Biology and research > Magnesium Research > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Biology and research
Magnesium Research
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

Oral magnesium supplementation decreases alanine aminotransferase levels in obese women


Magnesium Research. Volume 23, Number 2, 90-6, June 2010, original article

Full Text  

Author(s) : Heriberto Rodriguez-Hernandez, Miriam Cervantes-Huerta, Martha Rodriguez-Moran, Fernando Guerrero-Romero

Summary : To evaluate the effect of oral supplementation with magnesium chloride on the systemic and hepatic inflammation, 38 non-hypertensive obese women aged 30 to 65 years were allocated into groups with and without hypomagnesemia. Hypomagnesemic women drank 50 mL of 5% solution of MgCl 2 equivalent to 450 mg of elemental magnesium. Low-carbohydrate diets and physical activity were indicated for women in both groups. Chronic diarrhea, alcohol intake, use of diuretics, previous oral magnesium supplementation, hepatic disease, and renal damage were exclusion criteria. Hypomagnesemia is defined by serum magnesium concentrations ≤ 1.8 mg/dL, hepatic inflammation by serum alanine aminotransferase (ALT) levels ≥ 40 U/L, and systemic inflammation by serum high-sensitivity C reactive protein (hs-CRP) concentration ≥ 3 mg/L. At baseline (p \= 0.06) and final of follow-up (p \= 0.80), there were no significant differences by body mass index between the groups in the study. In the same way, at baseline ALT (48.1 ± 25.5 and 34.6 ± 24.1 U/L, p \= 0.14) and hs-CRP (9.4 ± 6.0 and 7.9 ± 5.9 mg/dL, p \= 0.47) levels were similar in the supplemented and non-supplemented women. In the magnesium group, ALT (24.3 ± 10.3 and 34.8 ± 13.6 U/L, p \= 0.02) levels, but not hs-CRP (5.2 ± 1.9 and 8.0 ± 5.6 mg/L, p \= 0.08) reached significantly lower levels, in the fourth month of treatment, than in women in the control group. The adjusted odds ratios between the improvement in serum magnesium and reduction in ALT and hs-CRP levels were 0.56 (95% CI: 0.3-0.9) and 0.93 (95% CI: 0.6-29.9), respectively. Results of this study show that in hypomagnesemic obese women, oral supplementation with magnesium chloride reduces plasma ALT levels\; hs-CRP levels only show a reduction trend.

Keywords : systemic inflammation, hepatic inflammation, hs-CRP, ALT, magnesium, magnesium chloride

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]